Review
Management options
Anthracycline-induced cardiomyopathy
N G Fisher, A J Marshall
South West
Cardiothoracic Unit, Derriford Hospital, Plymouth, Devon, UK
Accepted 5 November
1998
Anthracycline cardiomyopathy is less frequently encountered
nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a
condition that will persist due to the sensitivity of some patients to
these drugs and the necessity for large doses to be used for certain
individuals. We have demonstrated the benefit of angiotensin-converting
enzyme inhibitor therapy and would consider introducing these compounds
at the earliest opportunity. The use of probucol and vitamins as
antioxidants capable of preventing the onset of cardiomyopathy in
humans appears to require further investigation but may significantly
reduce the incidence of this condition in the future.
Keywords: anthracycline; cardiomyopathy
© 1999 by The Fellowship of Postgraduate Medicine
This article has been cited by other articles:
-
Simunek, T., Klimtova, I., Kaplanova, J., Mazurova, Y., Adamcova, M., Sterba, M., Hrdina, R., Gersl, V.
(2004). Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail
6: 377-387
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
